Plain-English translation of NCT06765616 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining a medication called Adebrelimab with radiation therapy and chemotherapy can help people with locally advanced rectal cancer before surgery. Adebrelimab is an immunotherapy drug designed to help your immune system fight cancer cells. The goal is to see if this combination approach shrinks tumors and improves outcomes before you have surgery to remove the cancer.
Standard treatment for advanced rectal cancer involves radiation, chemotherapy, and surgery, but researchers want to see if adding an immunotherapy medication can make this treatment more effective at controlling the disease and potentially improving long-term survival.
You likely qualify if…
You likely don't qualify if…
You would receive 6 cycles of treatment, each lasting 3 weeks. During each cycle, you would receive the immunotherapy medication by IV infusion, take chemotherapy pills by mouth for 2 weeks, and receive 5 radiation treatments (one per week). After completing all 6 cycles, you would have surgery 2–3 weeks later to remove the remaining cancer. Throughout the trial, you would have regular blood tests, imaging scans, and clinic visits to monitor how you're responding and to check for any side effects.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
China